Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Filings indexed 1,095 across all filing types
Latest filing 2025-11-06 Regulatory Filings
Country US United States of America
Listing US NVAX

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2025-11-06 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-06 English
FORM 8-K
Regulatory Filings
2025-11-04 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-10-30 English
FORM 8-K
Regulatory Filings
2025-10-22 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.